Q-omics provides the consensus-scored PFKFB3 profile across patient tissues and cancer cell-line models. PFKFB3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PFKFB3 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, PFKFB3 RNA expression shows 18,906 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, COAD, and ACC as cancer lineages where PFKFB3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PFKFB3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PFKFB3 survival associations across molecular data types. PFKFB3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PFKFB3 RNA expression–survival associations across cancer types. High PFKFB3 expression shows unfavorable associations in KIRP, UVM, ACC and COAD, but favorable associations in KIRC and SCLC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for PFKFB3 RNA expression.
This table summarizes PFKFB3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PFKFB3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PFKFB3 shows lower tumor expression in KICH, BRCA and LUSC and higher tumor expression in COAD, HNSC and THCA. The COAD box plot shows higher PFKFB3 RNA expression in tumor versus normal tissue (log2 FC = +0.897, t-test p < 0.001).
This table shows molecular features associated with PFKFB3 in patient tissues and cancer cell lines. In patient samples, PFKFB3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PFKFB3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
